The Hydroxypyridinone Iron Chelator CP94 Can Enhance PpIX-induced PDT of Cultured Human Glioma Cells

被引:42
作者
Blake, Emma [1 ]
Curnow, Alison [1 ]
机构
[1] Univ Exeter, Peninsula Med Sch, Knowledge Spa, Royal Cornwall Hosp, Truro, Cornwall, England
关键词
MEDIATED PHOTODYNAMIC THERAPY; NORMAL RAT COLON; 5-AMINOLEVULINIC ACID; PROTOPORPHYRIN-IX; BRAIN-TUMORS; CLINICAL-USE; IN-VITRO; ALA; FLUORESCENCE; MECHANISMS;
D O I
10.1111/j.1751-1097.2010.00770.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Photodynamic therapy (PDT) with the pro-drugs 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) utilizes the combined interaction of a photosensitizer, light and molecular oxygen to ablate tumor tissue. To potentially increase accumulation of the photosensitizer, protoporphyrin IX (PpIX), within tumor cells an iron chelator can be employed. This study analyzed the effects of ALA/MAL-induced PDT combined with the iron chelator 1, 2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94) on the accumulation of PpIX in human glioma cells in vitro. Cells were incubated for 0, 3 and 6 h with various concentrations of ALA/MAL with or without CP94 and the resulting accumulations of PpIX, which naturally fluoresces, were quantified prior to and following light irradiation. In addition, counts of viable cells were recorded. The use of CP94 in combination with ALA/MAL produced significant enhancements of PpIX fluorescence in human glioma cells. At the highest concentrations of each prodrug, CP94 enhanced PpIX fluorescence significantly at 3 h for ALA and by more than 50% at 6 h for MAL. Cells subsequently treated with ALA/MAL-induced PDT in combination with CP94 produced the greatest cytotoxicity. It is therefore concluded that with further study CP94 may be a useful adjuvant to photodiagnosis and/or PpIX-induced PDT treatment of glioma.
引用
收藏
页码:1154 / 1160
页数:7
相关论文
共 35 条
[1]  
AGENCY EM, 2007, EUROPEAN PUBLIC ASSE
[2]  
Al-Waili NS, 2005, MED SCI MONITOR, V11, pRA279
[3]   The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells [J].
Berg, K ;
Anholt, H ;
Bech, O ;
Moan, J .
BRITISH JOURNAL OF CANCER, 1996, 74 (05) :688-697
[4]  
BRITTENHAM GM, 1992, BLOOD, V80, P569
[5]   Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma [J].
Campbell, S. M. ;
Morton, C. A. ;
Alyahya, R. ;
Horton, S. ;
Pye, A. ;
Curnow, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (02) :387-393
[6]   Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents [J].
Curnow, A ;
McIlroy, BW ;
Postle-Hacon, MJ ;
Porter, JB ;
MacRobert, AJ ;
Bown, SG .
BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1278-1282
[7]  
Curnow A, 1999, PHOTOCHEM PHOTOBIOL, V69, P71
[8]   ALA and Photofrin® fluorescence-guided resection and repetitive PDT in glioblastoma multiforme:: a single centre Phase III randomised controlled trial [J].
Eljamel, M. Sam ;
Goodman, Carol ;
Moseley, Harry .
LASERS IN MEDICAL SCIENCE, 2008, 23 (04) :361-367
[9]   Transport of 5-aminolevulinic acid between blood and brain [J].
Ennis, SR ;
Novotny, A ;
Xiang, J ;
Shakui, P ;
Masada, T ;
Stummer, W ;
Smith, DE ;
Keep, RF .
BRAIN RESEARCH, 2003, 959 (02) :226-234
[10]   The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2-dimethyl-, 1,2-diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat [J].
Fredenburg, AM ;
Sethi, RK ;
Allen, DD ;
Yokel, RA .
TOXICOLOGY, 1996, 108 (03) :191-199